Abstract
Gemcitabine administered as a weekly 1,000 mg/m2 30 minutes infusion is considered as the standard treatment of non resectable pancreatic adenocarcinoma. However, the limited results obtained with this standard therapy justify gemcitabine-based combinations studies. We summarize the results of studies combining gemcitabine with 5FU, docetaxel, platinum-compounds, irinotecan and epirubicin. Some combinations seem to achieve an interesting efficacy, and are now compared to gemcitabine alone.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives*
-
Capecitabine
-
Cisplatin / therapeutic use
-
Clinical Trials, Phase II as Topic
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / adverse effects
-
Deoxycytidine / analogs & derivatives*
-
Docetaxel
-
Drug Administration Routes
-
Epirubicin / administration & dosage
-
Fluorouracil / administration & dosage
-
Fluorouracil / adverse effects
-
Gemcitabine
-
Humans
-
Irinotecan
-
Multicenter Studies as Topic
-
Organoplatinum Compounds / administration & dosage
-
Oxaliplatin
-
Paclitaxel / administration & dosage
-
Paclitaxel / analogs & derivatives*
-
Palliative Care
-
Pancreatic Neoplasms / drug therapy*
-
Randomized Controlled Trials as Topic
-
Taxoids*
-
Treatment Outcome
Substances
-
Organoplatinum Compounds
-
Taxoids
-
Oxaliplatin
-
Deoxycytidine
-
Docetaxel
-
Epirubicin
-
Capecitabine
-
Irinotecan
-
Paclitaxel
-
Cisplatin
-
Fluorouracil
-
Camptothecin
-
Gemcitabine